Indicated for: Secondary hyperparathyroidism
Status: In market (Asia)
Rights: Kyowa Hakko Kirin

Following review by the Pharmaceuticals and Medical Devices Agency (PMDA), Japan's Ministry of Health, Labor and Welfare (MHLW) approved Regpara^® (cinacalcet HCl) for the treatment of patients with secondary hyperparathyroidism during dialysis therapy. Kyowa Hakko Kirin began selling cinacalcet HCl in early 2008. In February 2010, NPS sold its royalty rights from sales of Regpara^® to an affiliate of DRI Capital or DRI for $38.4 million. Royalties will revert to the company if DRI receives cumulative royalties of $96 million or 2.5 times the amount paid.